Related Experiment Videos
Allogeneic umbilical cord blood transplantation
1Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis 55455, USA.
Cancer Treatment and Research
|January 1, 1997
Summary
Umbilical cord blood offers a safe, readily available source of hematopoietic stem cells. Early data suggest it may reduce graft-versus-host disease (GVHD) risks in transplantation.
Area of Science:
- Hematology
- Transplantation immunology
- Stem cell biology
Background:
- Growing interest in umbilical cord blood (UCB) as an alternative hematopoietic stem cell source.
- UCB offers advantages: low viral contamination, easy availability, and no donor risk.
- Potential to overcome donor shortages and reduce transplantation risks.
Purpose of the Study:
- To evaluate the potential of UCB hematopoietic stem cells in transplantation.
- To explore UCB's role in reducing graft-versus-host disease (GVHD) incidence and severity.
- To assess UCB as a source for gene therapy and address ethnic/racial donor disparities.
Main Methods:
- Review of current clinical experience and laboratory findings with UCB transplantation.
- Analysis of UCB collection, storage, and banking programs.
- Comparison of UCB transplantation outcomes with traditional bone marrow transplantation.
Main Results:
- UCB transplantation has shown a low incidence of clinically significant GVHD, even with HLA-disparate grafts.
- Large-scale UCB collection and banking are now feasible, reducing donor search times.
- UCB may be as effective as bone marrow in pediatric recipients, though more data are needed.
Conclusions:
- UCB represents a promising alternative for hematopoietic stem cell transplantation.
- UCB has the potential to significantly reduce GVHD and address donor shortages.
- Further research and patient data are required to fully establish UCB's long-term efficacy and safety.